AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices.
ByAinvest
Wednesday, Aug 13, 2025 11:50 am ET1min read
Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. regarding potential securities fraud or unlawful business practices. The investigation concerns the Company's Phase 3 study of UX143 for osteogenesis imperfecta, which is progressing toward a final analysis expected by the end of the year. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
New York, Aug. 11, 2025 — Pomerantz LLP has initiated an investigation into claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The investigation focuses on whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices [1].The investigation is prompted by recent developments in Ultragenyx's Phase 3 clinical trial of UX143, a drug candidate for osteogenesis imperfecta (OI). On July 9, 2025, the company and its development partner Mereo BioPharma Group plc announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study is progressing toward a final analysis expected by the end of the year. Following this announcement, Ultragenyx's stock price fell by $10.41 per share, or 25.11%, to close at $31.04 on July 10, 2025 [2].
Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about the investigation.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, and Paris, is recognized for its expertise in corporate, securities, and antitrust class litigation. The firm has a history of recovering multimillion-dollar damages for class members in securities fraud cases [1].
References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-ra-ce7c5ed2d18cf520
[2] https://www.bakersfield.com/ap/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx/article_52d5f5b2-8791-526e-a076-b4c868d96c33.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet